REVIEW ARTICLE

New Trends in Inflammatory Bowel Disease

Carolina Palmela, Joana Torres, Marilia Cravo *

Gastroenterology Department, Surgical Department, Hospital Beatriz Ângelo, Loures, Portugal

Received 17 January 2015; accepted 12 March 2015
Available online 11 May 2015

KEYWORDS
Antibodies; Monoclonal; Colitis, Ulcerative; Crohn Disease; Inflammatory Bowel Diseases; Molecular Targeted Therapy; Drug Monitoring

Abstract Inflammatory bowel disease (IBD) is a chronic idiopathic inflammatory disease of the gastrointestinal (GI) tract. In the past decade a shift in the treatment paradigm of IBD has ensued. The availability of drugs capable of inducing mucosal healing, combined with the recognition that IBD is not an intermittent disease, but rather a progressive one causing bowel damage and disability, led us to a more stringent strategy. Tailored therapy with more aggressive treatment in high-risk patients, treating beyond symptoms, intervening early before damage occurs, optimizing therapeutic regimens, and actively pursuing sustained remission and sustained control of inflammation are strategies that are slowly being incorporated in our clinical practice. Furthermore, new drugs targeting different immunological pathways, such as vedolizumab, have recently been approved and therefore more therapeutic resources for patients failing anti-tumour necrosis factor alpha (anti-TNFα) agents will be available.

The future years look promising for IBD. Hopefully the new trends in IBD management, combined with new drugs, will make possible to change the course of disease and provide better therapy and quality of life for patients suffering from this disabling disease.

© 2015 Sociedade Portuguesa de Gastrenterologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PALAVRAS CHAVE
Colite Ulcerosa; Doença de Crohn; Doença Inflamatória Intestinal; Terapia Molecular Dirigida; Monitorização de Medicamentos

Novas Estratégias Terapêuticas na Doença Inflamatória do Intestino

Resumo A doença inflamatória intestinal (DII) é uma doença idiópática crónica e incapacitante do trato gastrointestinal. Na última década tem-se assistido a uma modificação nas estratégias de abordagem e tratamento do doente com DII. O desenvolvimento de fármacos potentes com capacidade de induzir a cicatrização da mucosa, aliado ao reconhecimento do carácter progressivo da doença, com dano intestinal irreversível e compromisso da qualidade de vida, conduziu à adoção de estratégias mais rigorosas. Tem-se assistido à incorporação de novas estratégias na prática clínica atual, tais como terapêutica individualizada mais agressiva em doentes com mau prognóstico mais precocemente, uso de outros objetivos terapêuticos para além da remissão
sintomática, intervenção precoce para evitar o desenvolvimento de dano intestinal irreversível, otimização da terapêutica com objetivo de alcançar a remissão sustentada e o controlo da inflamação. Adicionalmente, a aprovação de novos fármacos com ação em vias imunológicas alternativas, como o vedolizumab, permitirá alargar o espectro terapêutico no doente não respondedor a agentes anti-factor de necrose tumoral alfa.

O futuro parece promissor na área da DII. É expectável que as novas estratégias de abordagem do doente com DII, aliadas ao desenvolvimento de novos fármacos, permitam alterar o curso natural da doença, evitando o dano intestinal irreversível e possibilitando a melhoria da qualidade de vida destes doentes.

© 2015 Sociedade Portuguesa de Gastrenterologia. Publicado por Elsevier España, S.L.U. Este é um artigo Open Access sob a licença de CC BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

In the past years, inflammatory bowel disease (IBD) has witnessed major advances both at the fundamental and clinical levels. Key discoveries in disease’s pathogenesis led to the development and refinement of therapeutic strategies paving the way for a new era in targeted drug development.¹

Therapeutic management in IBD has also suffered a major shift in the past years. The traditional paradigm of gradually introducing the least toxic but less powerful drugs and repeated courses of steroids has progressively moved to favour the early introduction of immunomodulation and most recently biologic therapy, in order to modify the natural history of disease.²

The discovery and introduction of anti-TNFα agents have constituted a major breakthrough for patients and clinicians. These novel therapies offer the ability to induce and maintain remission, heal the mucosa, and reduce surgeries and hospitalizations.³ However, many patients will still be refractory to treatment or lose response over time. Therefore, therapeutic drug monitoring, as a way of optimizing anti-TNFα use, has been an area of intensive research. Furthermore, new drugs are expected to hit the clinic. Vedolizumab, an anti-integrin, is eagerly awaited for patients who have failed anti-TNFα and it has shown to be able to induce and maintain remission in patients with Crohn’s disease (CD) and ulcerative colitis (UC).

We are increasingly using prognostic and predictive factors at diagnosis and during follow-up to guide our therapeutic decisions. We now recognize that in order to block disease progression, it is crucial to intervene early before damage occurs.

In this review we will briefly discuss new therapies in IBD, and we will focus on new trends that are emerging in the treatment of IBD patients, with the goal of optimizing current therapeutic strategies and blocking disease progression.

2. Prognostication in IBD

IBD is a heterogeneous condition with a highly variable clinical course, with some patients following a mild course while others experience early and aggressive disease progression.⁴⁻⁶ Therapeutic strategies in IBD result from a delicate and difficult balance between benefits and risks of more aggressive therapies. Early treatment with immunomodulators and/or anti-TNFα is expected to change the natural history of disease, especially for CD, but with the risk of overtreating some patients with mild-moderate disease who would not need such intensive therapy. Therefore, the possibility of patient profiling using prognostic factors at diagnosis (including clinical, laboratory and imaging criteria) for the selection of the best suited candidates for early aggressive therapies is of main importance (Tables 1 and 2).⁷,⁸

Several definitions of poor prognosis in CD have been suggested. Disabling CD was arbitrarily defined by Beaugerie et al⁷ in 2006 by the presence of at least one of the following criteria in the 5-year period after diagnosis: More than two steroid courses and/or steroid dependency; further hospitalization after diagnosis for flare up or complications of the disease; presence of disabling chronic symptoms; need for immunosuppressive therapy; and intestinal resection or surgery for perianal disease. In a recent meta-analysis⁹ including 1961 patients,⁹⁻¹¹ the demographic and clinical characteristics associated with significantly higher risk of developing disabling disease at five years after initial diagnosis were: young age (<40 years) at diagnosis, initial requirement of steroids for treating the first flare and perianal disease.⁹

In 2012, Zallot and Peyrin-Biroulet¹² suggested a different definition for complicated IBD. Complicated CD was defined as the presence of bowel damage (stricture, abscess and/or fistula) and/or the requirement for surgery and/or the presence of extra-intestinal manifestations. Clinical factors associated with complicated CD include young age at diagnosis, small bowel disease (ileal and/or ileocolonic), upper gastrointestinal extent, stricture or penetrating behaviour, perianal disease, severe endoscopic lesions (deep ulcerations) at index colonoscopy and smoking.¹²⁻¹⁶

Complicated UC was defined as the development of colon cancer and/or the need for surgery (colectomy) and/or the presence of extra-intestinal manifestations.¹³ Clinical predictors for complicated UC include young age at diagnosis, male gender, extensive colitis, severe disease activity at diagnosis, high histological inflammation score, the presence of primary sclerosing cholangitis, steroid use and steroid resistance.⁴,¹²,¹³,¹⁷⁻²¹
Table 1. Clinical, demographic and endoscopic prognostic predictors in Crohn’s disease (CD) and the associated impact on disease course.

<table>
<thead>
<tr>
<th>Prognostic factor</th>
<th>Impact on disease course</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Crohn’s disease</strong></td>
<td></td>
</tr>
<tr>
<td>Young age (&lt;40 years) at diagnosis</td>
<td>• Disabling CD&lt;sup&gt;9,11,13&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>• Complicated CD (surgery included)&lt;sup&gt;12,13&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>• Disease recurrence&lt;sup&gt;13&lt;/sup&gt;</td>
</tr>
<tr>
<td>Stricturing behaviour (B2)</td>
<td>• Complicated CD (surgery included)&lt;sup&gt;12,13&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>• Severe CD&lt;sup&gt;10&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>• Disease recurrence&lt;sup&gt;13&lt;/sup&gt;</td>
</tr>
<tr>
<td>Penetrating behaviour (B3)</td>
<td>• Complicated CD (including surgery and disease behaviour progression)&lt;sup&gt;12,13,15,16&lt;/sup&gt;</td>
</tr>
<tr>
<td>Ileal disease (L1)</td>
<td></td>
</tr>
<tr>
<td>Ileocolonic disease (L3)</td>
<td>• Disabling CD&lt;sup&gt;10&lt;/sup&gt;</td>
</tr>
<tr>
<td>Upper GI extent (L4)</td>
<td>• Complicated CD (surgery included)&lt;sup&gt;12,13&lt;/sup&gt;</td>
</tr>
<tr>
<td>Perianal disease</td>
<td>• Disabling CD&lt;sup&gt;9-11&lt;/sup&gt;</td>
</tr>
<tr>
<td>Smoking</td>
<td>• Complicated CD&lt;sup&gt;12,15&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>• Complicated CD&lt;sup&gt;12,15&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>• Higher recurrence rate (surgical or non-surgical)&lt;sup&gt;13,15&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>• More frequent perianal disease&lt;sup&gt;16&lt;/sup&gt;</td>
</tr>
<tr>
<td>Weight loss &gt;5 kg at diagnosis</td>
<td>• Severe CD&lt;sup&gt;10&lt;/sup&gt;</td>
</tr>
<tr>
<td>High number of flares per year</td>
<td>• Progression to penetrating behaviour and development of perianal disease&lt;sup&gt;16&lt;/sup&gt;</td>
</tr>
<tr>
<td>Disease duration &gt;10 years</td>
<td>• Complicated CD&lt;sup&gt;15&lt;/sup&gt;</td>
</tr>
<tr>
<td>Severe endoscopic lesions (deep ulcerations) at index colonoscopy</td>
<td>• Increased rate of penetrating complications and surgery&lt;sup&gt;14&lt;/sup&gt;</td>
</tr>
<tr>
<td>Requirement of steroids for treating the first flare</td>
<td>• Disabling CD&lt;sup&gt;9-11&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

Table 2. Clinical, demographic and endoscopic prognostic predictors in ulcerative colitis (UC) and the associated impact on disease course.

<table>
<thead>
<tr>
<th>Prognostic factor</th>
<th>Impact on disease course</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ulcerative colitis</strong></td>
<td></td>
</tr>
<tr>
<td>Young age at diagnosis</td>
<td>• Complicated UC (including colectomy)&lt;sup&gt;12&lt;/sup&gt;</td>
</tr>
<tr>
<td>Male gender</td>
<td>• Colectomy&lt;sup&gt;20,21&lt;/sup&gt;</td>
</tr>
<tr>
<td>Extensive colitis</td>
<td>• Complicated UC (including colectomy)&lt;sup&gt;6,12,13&lt;/sup&gt;</td>
</tr>
<tr>
<td>Severe disease activity at diagnosis</td>
<td>• Colectomy&lt;sup&gt;20&lt;/sup&gt;</td>
</tr>
<tr>
<td>High histological inflammation score</td>
<td>• Colectomy&lt;sup&gt;19&lt;/sup&gt;</td>
</tr>
<tr>
<td>Disease duration &gt;10 years</td>
<td>• Colectomy&lt;sup&gt;20&lt;/sup&gt;</td>
</tr>
<tr>
<td>Steroid use</td>
<td>• Colectomy&lt;sup&gt;19&lt;/sup&gt;</td>
</tr>
<tr>
<td>Steroid resistance</td>
<td>• Colectomy&lt;sup&gt;20&lt;/sup&gt;</td>
</tr>
<tr>
<td>Primary sclerosing cholangitis</td>
<td>• Complicated UC (colorectal cancer)&lt;sup&gt;17&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

3. New endpoints in IBD

In CD, subclinical inflammation often persists and there is a progressive evolution to structural and irreversible bowel damage, which frequently requires surgical intervention. Current clinical and endoscopic scores only measure disease activity at a specific time. The recently published Lémann Index (Crohn’s disease digestive tract damage score) is the first tool that aims to measure the cumulative structural bowel damage, including strictures, penetrating lesions (abcesses and fistulæ), and surgical resection. This evaluation includes damage location, extent, severity, progression and reversibility (measured by imaging techniques and the need of resection). In each organ (upper GI tract, small bowel, colon/rectum and anus) the score ranges from 0.0 (absence of damage) to 10.0 (complete resection). As expected, the median Lémann Index increases with disease duration. There are numerous future potential applications for this index, including the assessment of disease progression and patients’ heterogeneity, the identification of parameters at diagnosis associated with a high risk of rapid progression, and the impact of therapy strategies on long-term outcomes.

Another emerging endpoint is disability, as an objective way of measuring the impairments, activity limitations, and participation restrictions that are experienced by patients suffering from IBD in different areas or health domains. In the years to come, it is likely that predictors of bowel damage and disability will be identified, as well as the impact of new drugs and therapeutic strategies in preventing them.
4. New therapeutic strategies – tight control monitoring and the "treat-to-target" strategy

The traditional symptom-oriented management has shown not to improve long-term outcomes in IBD. Therefore a more proactive attitude is emerging in IBD, similar to other chronic diseases.

The "treat-to-target" strategy is based on frequent assessment of disease activity, using objective markers of inflammation and subsequently adjusting therapy accordingly to reach the pre-established target. The ultimate objective of this approach is to modify the natural course of the disease. The ideal target to achieve in IBD is still a matter of debate and likely to evolve. So far, mucosal healing (MH) seems to be the best established therapeutic endpoint both in UC and CD. The definition of MH used in most clinical trials is the "complete absence of all inflammatory and ulcerative lesions". Several clinical trials and population-based studies have demonstrated that MH achievement is associated with better outcomes, such as a lower incidence of disease relapse, hospitalization and surgery.

Due to the invasive nature and cost of endoscopy, several other treatment goals have emerged, such as the use of cross-sectional imaging and inflammation biomarkers. Although new endoscopic and therapeutic techniques, as deep enteroscopy, have a specific role in diagnosis and treatment in IBD, magnetic resonance enterography (MRE), computed tomography (CT) and ultrasound (US) may be alternatives to ileocolonoscopy. They have the advantages of being less invasive, able to assess the small bowel and providing information about the transmural nature of inflammation. CT has a similar accuracy to MRE for assessing disease activity in CD, but the risk of radiation exposure limits its use as a monitoring tool. Rimola et al suggested and validated a Magnetic Resonance Index of Activity (MaRIA) score to quantify CD activity based on MRI findings in each ileocolonic segment, and found a strong correlation with CDEIS (Crohn's Disease Endoscopic Index of Severity). In a systematic review by Panes et al, including 16 studies with a total of 1629 segments assessed, the overall sensitivity and specificity of MRE for the assessment of disease activity was 80% and 89%, respectively. However, the accuracy of MRI to monitor therapeutic responses has not yet been fully ascertained. In a recent multicentre prospective study with 48 patients receiving corticosteroids or anti-TNFα, the disease activity was assessed before and after treatment using MRE (MaRIA score) and ileocolonoscopy (CDEIS). The authors found a significant correlation between imaging activity index and CDEIS scores, with MRE determining ulcer healing with 90% accuracy.

Non-invasive biomarkers of intestinal and systemic inflammation may represent an attractive alternative for evaluating disease activity, independently of disease location. The most broadly used and extensively studied biomarkers are faecal calprotectin (FC) and serum C-reactive protein (CRP). There is a correlation between these markers concentration and endoscopic lesions, risk of relapse, risk of complications and response to therapy. Elevated biomarker levels are associated with endoscopic and histologic bowel inflammation. In general, this correlation is higher when using faecal biomarkers, such as calprotectin. Nonetheless, in CD patients with small bowel involvement, FC seems to have a weaker correlation with endoscopic activity. In such cases, CRP levels may better reflect the transmural inflammatory process. The association between non-invasive biomarkers levels and intestinal inflammation is not always accurate. Up to one-third of patients with intestinal inflammation may have normal CRP levels. However, in CD patients who have a raised CRP concentration at baseline, changes in CRP levels may provide useful information in monitoring response to treatment. Jürgens et al showed that in CD patients treated with infliximab, early normalization of CRP levels correlated with sustained long-term response to therapy, while a persisting increase in CRP under therapy was associated with a high likelihood of relapse. Biomarkers have been studied less in the postoperative setting. The Poccer study was a prospective study aiming at identifying the best strategy for prevention of post-operative CD. As a part of this study several biomarkers were measured. No correlation between increased levels of CRP and disease recurrence was observed. Whereas, following surgery, levels of FC >100 μg/g indicated endoscopic recurrence with 89% sensitivity and 58% specificity, and a negative predictive value of 91%.

CRP and faecal calprotectin may be best used as screening tool to decide the ideal timing for endoscopic or cross-sectional imaging reassessment. A recent meta-study analysing data from six studies (551 CD patients) found that in patients with symptoms (CDAI >220), CRP <5 mg/l or calprotectin <200 μg/g predicted a CDEIS ≤6 with a sensitivity and specificity of 83% and 71%, respectively. Therefore with the use of appropriate threshold levels, these biomarkers could help to make decisions about the ideal timing of endoscopy.

Still, the reliability of these biomarkers to predict MH is not fully established. Depending on the calprotectin concentration threshold used, its sensitivity and specificity in predicting absence of MH were 70–100% and 44–100%, respectively. Recently, D’Haens et al suggested a faecal calprotectin cut-off value of 250 μg/g levels above this concentration predicted large ulcers in CD (sensitivity 60%, specificity 80%) and active mucosal disease activity (Mayo >0) in UC (sensitivity 71%, specificity 100%). In CD, a concentration <250 μg/g predicted MH (CDEIS <3) with a sensitivity of 94% and a specificity of 62%. In a subanalysis of the STORI cohort the combination of faecal calprotectin (at a threshold of 250 μg/g) and CRP (at a threshold of 5 mg/l) has shown to improve the ability to predict mucosal healing (sensitivity 70%, specificity 70%).

There are some issues that need to be defined, namely the optimal time frame for assessment of treatment goals in a "treat-to-target" strategy. Using MH as the target, recent trials in CD found that in patients under treatment with immunosuppressives, anti-TNFα or a combination of both, the time frame for achieving MH ranged from 10 to 26 weeks. Allen and Peyrin-Biroulet suggested that, independently of the method used (endoscopy, MRE, CRP and/or faecal calprotectin), the treatment goal should be first assessed at 3–6 months after introduction of disease-modifying agents. Bouguen et al proposed that, in CD patients at high risk for disease-related progression or
complications, MH should be assessed every 6 months until the disappearance of ulceration and every 1–2 years thereafter.

Another controversy issue in this “treat-to-target” strategy is the management of insufficiently healed patients. It is not yet clear whether patients in clinical remission and with residual mucosal inflammation have a worse prognosis than patients with complete MH. The minimal degree of mucosal improvement required to alter outcomes is not yet known. Ferrante et al., in a post hoc analysis of the SONIC trial data, showed that a decrease of at least 50% in CDEIS from baseline to week 26 (endoscopic response) was associated with steroid-free remission at week 50, with a similar specificity and sensitivity to mucosal healing (absence of ulcers). The impact of this finding on long-term outcomes needs to be clarified.

5. New drugs in IBD

An important step in the pathogenesis of IBD involves the migration of leukocytes into the gut. The recruitment of T-cells and other inflammatory cells to the intestinal mucosa leads to pro-inflammatory cytokine production, affecting the endothelial barrier and inducing cell apoptosis. Integrin antagonists are anti-adhesion molecules which block the interaction between inflammatory and endothelial cells, thereby disrupting trafficking of T-lymphocytes into the inflamed gut.

The first anti-adhesion agent that proved to be effective in the treatment of IBD was natalizumab. Natalizumab is an anti-α4-integrin IgG4 non-gut-selective antibody, also used for treating multiple sclerosis, which binds to α4β1 and α4β7 integrins, inhibiting T-lymphocyte adhesion to vascular cell adhesion molecule-1 (VCAM-1) and mucosal addressin cell adhesion molecule-1 (MADCAM-1). The initial enthusiasm surrounding its success was halted by reports of the aggressive progressive multifocal leukoencephalopathy. Nevertheless, this agent provided proof of concept and paved the way for the development of new anti-adhesion agents, such as vedolizumab (VDZ). VDZ is a humanised anti-α4β7 integrin-IgG1 monoclonal antibody that binds to MADCAM-1. Unlike natalizumab, VDZ is gut specific, providing gut-selective immunosuppression with similar efficacy, with a lower risk of systemic infection. A recent study using the anti-MADCAM-1 antibody showed that treatment with this drug does not affect the populations of CD4 and CD8 lymphocytes in the cerebrospinal fluid.

The results of the phase III, randomized, placebo-controlled trials (RCT) on the induction and maintenance of VDZ in UC and CD (the GEMINI I and II studies) have recently been published. Patients were randomized to VDZ at a dose of 300 mg or placebo at week 0 and week 2. During induction, at week 6, 75% of the patients on VDZ versus 58% of the patients on placebo achieved clinical response (p < 0.001). Rates of mucosal healing (Mayo score 0 or 1) were 80% for VDZ and 34% for placebo (p = 0.001). A second cohort of 521 patients received open-label VDZ at weeks 0 and 2, with disease evaluation at week 6. Responder from both cohorts were then randomized to receive drug every 4 or 8 weeks or placebo. A total of 41.8% and 44.8% maintained remission when receiving medication every 8 weeks and every 4 weeks, respectively; patients on placebo had maintenance of remission at a rate of 15.9% (p < 0.001 for the two VDZ groups, respectively, vs. placebo). Adverse events were similar in both groups.

In the CD induction study, 368 patients were randomized to 300 mg of VDZ or placebo at weeks 0 and 2. A second cohort of 747 patients received open-label VDZ. All patients were followed through 6 weeks. Patients on VDZ had a statistically significant difference in clinical remission of 14.5 versus 6.8% in placebo (p = 0.02) at week 6, but no difference in CDAI-100 response or reduction in mean C-reactive protein (CRP) levels at week 6. Patients from both cohorts with a clinical response at week 6 (461 patients) entered the maintenance trial and were randomized to receive VDZ every 8 weeks, or every 4 weeks, or placebo for up to 52 weeks. In the VDZ groups, 39% and 36.4% of those assigned to VDZ every 8 and 4 weeks, respectively, were in clinical remission at week 52, as compared with 21.6% assigned to placebo (p < 0.001 and p = 0.004 for the two VDZ groups, respectively. vs. placebo). There was also statistical significance in CDAI-100 response, and steroid-free remission at week 52 for both VDZ groups versus placebo (p < 0.001 and 0.004, respectively). Patients with prior anti-TNFα exposure had lower clinical response and remission rates at week 6 and week 52. In the CD studies, VDZ was associated with higher degree of adverse events than placebo.

Based on these studies, VDZ has received approval for marketing in CD and UC for patients not responding to one or more standard therapies (corticosteroids, immunomodulators, or tumour necrosis factor blocker medications) and is expected to arrive in the clinical practice very soon. How will VDZ be positioned in the treatment of IBD? So far no head-to-head trials are available comparing anti-TNFα to VDZ. For CD patients it is apparent from the RCT, that VDZ is not a good induction drug, because it may require a longer induction period to achieve a clinical response. Based on the pivotal trials, it will probably be reserved for CD patients with moderate to severe luminal disease not responding or losing response to anti-TNFα agents. Its use in perianal fistulising disease and as induction first-line agent will require further studies.

In UC, a meta-analysis including 7 double-blind placebo-controlled trials, with a total of 1502 patients (720 given placebo), showed that in patients with moderate to severe active UC naïve to biological therapy, VDZ has similar efficacy to the anti-TNFα antibodies infliximab, adalimumab, and golimumab for induction of response and remission and for maintenance of response and remission. This has however never been tested in real life. Likely VDZ will be reserved for the treatment of ulcerative colitis patients who fail one anti-TNFα, given its success in this population of patients and the low efficacy of a second anti-TNFα agent to induce a clinical response in this setting.

Many more promising treatments are expected to arrive in the next years. Erolizumab, which is also an anti-integrin, is currently undergoing phase III trials. Tofacitinib, an oral JAK inhibitor, ustekinumab, and anti-IL12/IL23 are also undergoing clinical trials. Hopefully some of these new drugs will reach the clinic and become part of the therapeutic arsenal in IBD.
6. Therapeutic drug monitoring – optimizing what we currently have

Loss of response (LOR) is an important issue of anti-TNFα therapy.64 Empiric escalation of the drug either by increasing the dose or shortening the interval has been used in the past to manage loss of response but it is increasingly being replaced by therapeutic drug monitoring (TDM). In a significant number of patients, loss of response is mediated through formation of anti-drug antibodies (ADA).67 Scheduled anti-TNF administration, rather than episodic, as well as association with an immunosuppressive agent, are the main strategies to reduce ADA formation.50

Commercially available assays for measuring drug metabolites and anti-drug antibodies (ADA) for infliximab (IFX) and adalimumab are now available and may be helpful in guiding treatment strategies in a more customized, economic and rational way.68,69

Among the risk factors for LOR, immunogenicity is far the most important. Despite the well known association between ADA formation, lower trough levels and LOR, only recently has the kinetics of anti-drug antibody formation been described.70 In this study by Ungar et al, among 125 patients (98 CD, 27 UC) treated with IFX, sera were collected before each infusion and analyzed for ADA and IFX trough levels. Around 46% of patients developed ADA, and 90% did so in the first 12 months of therapy. The formation of ADA heralded LOR in 54% of patients with a median delay of 2 months. Interestingly, the median time to ADA formation was 1.5 months (range 0.5–31 months), meaning that 75% of patients by week 22 of treatment had developed ADA.

Based on ADA and trough levels most authorities recommend the following approach to patients presenting with LOR:71: (1) patients with low drug levels should have dose intensification, (2) patients with high concentrations of ADA should switch to another anti-TNFα molecule, and (3) patients who present a therapeutic drug concentration without ADA should discontinue anti-TNFα therapy and switch to another class of medications or consider surgical options, after active disease is objectively confirmed. We must bear in mind some important aspects of this algorithm. In first place this strategy is mainly based on results obtained with the ELISA methodology, which is limited by the inability to measure ADA in the presence of circulating drug.72 Secondly, the optimal drug level associated with clinical response is still a matter of debate, as detection assays may vary between centers. Nevertheless trough levels for IFX of 3–7 μg/mL73 and 5–10 μg/mL24 have recently been suggested as a target for maintenance therapy for both UC and CD, respectively.75 For adalimumab 5.85 μg/mL has been suggested as an adequate trough level.76 Finally, this algorithm may not be applicable to almost one-third of patients with results outside the defined cut-off values.77

7. Therapy de-escalation

If a patient reaches sustained remission, there is an opportunity for treatment de-escalation. De-escalation strategies are increasingly being considered in clinical practice because of safety concerns (opportunistic infections and cancer78) and economic issues.79 However, proper de-escalation criteria are not yet defined. De-escalation strategies may include discontinuation of the immunosuppressant (IS), withdrawal of the anti-TNFα, or reducing the dose of one or both drugs.90

A randomized, controlled study evaluated the impact of IS discontinuation in CD patients receiving combination therapy with IFX and in remission for at least six months.91 The authors found that although patients who discontinued IS had higher C-reactive protein levels and lower IFX trough levels, there were similar proportions of patients needing a change in IFX regimen over 24 months in the two groups (60% and 55% in those who continued and interrupted IS, respectively).91

The STORI trial from the GETAID evaluated the impact of IFX discontinuation in 115 CD patients treated with IFX plus IS for more than one year and with steroid-free remission for more than six months.16 The authors found relapse rates of 44% and 52% over 1 year and 2 years after IFX discontinuation, respectively.16 In a multivariable analysis, risk factors for relapse included male gender, absence of surgical resection, leucocyte counts > 6.0 × 109 L−1, levels of haemoglobin ≤ 145 g/L, C-reactive protein ≥ 5.0 mg/L, faecal calprotectin ≥ 300 μg/g and absence of mucosal healing (CDEIS > 0).16 Re-treatment with IFX was found to be effective and well tolerated in 88% of patients who had relapsed.16 No prospective data in UC are available so far.

Therefore, in patients receiving combination therapy, relapse rate after IS withdrawal seems lower than after anti-TNFα discontinuation, therefore the former is considered preferable by some authors.79

A step-down approach based on IS or anti-TNFα dose reduction according to disease activity has been studied in rheumatology with conflicting results.80,82 Prospective studies in IBD are needed to assess the benefit of this approach. Finally, complete drug withdrawal would be the ultimate goal of therapy de-escalation in IBD. However, to date, treatment discontinuation in patients receiving monotherapy (with either IS or anti-TNFα) is not universally

![Figure 1](http://www.elsevier.es) New trends in IBD: (1) utilization of prognostic factors at diagnosis; (2) the use of a “treat-to-target” strategy and new endpoints in patient management; and (3) new drugs, therapeutic drug monitoring and therapy de-escalation.
recommended because of a high clinical relapse rate (30–60% at 12 months after IS withdrawal in IBD patients under IS alone).  

In conclusion, de-escalation treatment strategies should be mainly considered in highly selected CD patients with a high risk of severe adverse events and low risk of relapse after treatment withdrawal (deep remission: including clinical remission, biomarker normalization and complete mucosal healing). In the future, the ultimate target in IBD will probably be "complete" remission, including also histological and molecular healing. Nonetheless the prognostic value of histological remission as a treatment target in IBD needs to be confirmed and validated histological scores are needed.

8. Conclusions

New trends are emerging in IBD (Fig. 1), with the hope of changing natural history of disease. Among the new drugs expected to arrive in the next years, vedolizumab, etrolizumab, ustekinumab and tofacitinib appear to be the most promising.

A new paradigm moving towards disease modification in CD is emerging which includes early intensive (if necessary) treatment and tight disease control. Early treatment with immunosuppressants and/or biologics in patients with poor prognostic factors should be considered.

A "treat-to-target" strategy, based on frequent assessment of disease activity and subsequent adjustment of treatment accordingly, may modify the natural course of IBD. The use of monitoring tools such as endoscopy, cross-sectional imaging and biomarkers has not been prospectively validated and remains empirical. Mucosal healing appears to be an important treatment endpoint but there is a need for a validated universal definition and to use a standardized validated endoscopic score both in UC and CD. The use of non-invasive inflammatory biomarkers as well as blood drug levels may improve the efficacy of therapy monitoring. Further prospective studies to assess benefits and potential risks of a "treat-to-target" approach on long-term outcomes in IBD are needed.

Additionally, the increased use of immunomodulators, administered earlier and for longer periods, raised consideration about treatment de-escalation and safety of chronic immunosuppression. Predictors for relapse following therapy discontinuation in IBD are needed.

In conclusion, new endpoints are arising and new strategies aiming at the sustained suppression of inflammation, and involving disease activity monitoring in a "treat-to-target" approach are becoming increasingly incorporated in the daily clinical practice of treating IBD.

Conflicts of interests

The authors have no conflicts of interest to declare.

References


